title: Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma.
abstract: OBJECTIVE
  To investigate the role of platelet activation in the development of systemic sclerosis and the role of interferon-gamma (IFN gamma) in the inhibition of mitogenic activity induced by whole blood serum of patients with systemic sclerosis.
  
  
  METHODS
  The mitogenic activity of whole blood serum in the absence or presence of different concentrations of IFN gamma (a potent inhibitor of induced collagen synthesis in dermal fibroblasts) and platelet-poor plasma derived serum were tested on human dermal fibroblasts by measuring incorporation of [3H]thymidine. Platelet activation was determined by quantification of plasma beta-thromboglobulin (beta-TG) using a beta-TG radioimmunoassay kit.
  
  
  RESULTS
  The mitogenic activity was significantly increased in whole blood serum and in platelet-poor plasma derived serum of the patients compared with controls. In contrast, no significant increase in beta-TG concentration was observed in scleroderma platelet-poor plasma compared with control. Recombinant human IFN gamma had a greater inhibitory effect on the mitogenic activity induced by whole blood serum of patients than on that produced with control sera, at any concentration of IFN gamma tested.
  
  
  CONCLUSIONS
  Our results suggest that mitogenic activity observed in the plasma of sclerodermic patients could originate from cells other than platelets and could be involved in the development of fibrosis. The potent inhibitory effect of IFN gamma on this proliferative activity may account for the beneficial effect of this cytokine in the treatment of progressive systemic sclerosis.
authors: Hôpital Lariboisière, INSERM U 348, Paris, France.
authors: M
authors: M
authors: Bryckaert
authors: M
authors: M
authors: Fontenay
authors: F
authors: F
authors: Lioté
authors: S
authors: S
authors: Bellucci
authors: R
authors: R
authors: Carriou
authors: G
authors: G
authors: Tobelem
mesh_terms: D000328:Adult; D017675:CREST Syndrome / Q000097:blood; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005260:Female; D005347:Fibroblasts / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007371:Interferon-gamma / Q000494:pharmacology*; D008875:Middle Aged; D008938:Mitosis / Q000187:drug effects / Q000502:physiology*; D011994:Recombinant Proteins; D012595:Scleroderma, Systemic / Q000097:blood*; D012867:Skin / Q000473:pathology; D013936:Thymidine / Q000378:metabolism; D001620:beta-Thromboglobulin / Q000032:analysis
chemical_list: D011994:Recombinant Proteins; D001620:beta-Thromboglobulin; D007371:Interferon-gamma; D013936:Thymidine